Wall Street Zen Downgrades LENZ Therapeutics (NASDAQ:LENZ) to Sell

LENZ Therapeutics (NASDAQ:LENZ) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

Other research analysts also recently issued research reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of LENZ Therapeutics in a report on Thursday, January 22nd. HC Wainwright reiterated a “buy” rating on shares of LENZ Therapeutics in a research note on Monday, December 15th. Finally, Zacks Research cut shares of LENZ Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 20th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $56.40.

LENZ Therapeutics Trading Down 3.8%

Shares of LENZ opened at $11.59 on Friday. The firm’s fifty day simple moving average is $16.26 and its 200-day simple moving average is $28.59. The firm has a market capitalization of $362.65 million, a price-to-earnings ratio of -5.49 and a beta of 0.50. LENZ Therapeutics has a twelve month low of $11.50 and a twelve month high of $50.40.

Institutional Trading of LENZ Therapeutics

A number of large investors have recently bought and sold shares of LENZ. Quarry LP acquired a new position in LENZ Therapeutics in the third quarter valued at $27,000. Bfsg LLC purchased a new position in shares of LENZ Therapeutics during the third quarter worth about $30,000. State of Wyoming acquired a new position in LENZ Therapeutics in the 4th quarter valued at about $30,000. Caitong International Asset Management Co. Ltd purchased a new stake in LENZ Therapeutics during the 4th quarter valued at approximately $32,000. Finally, Osaic Holdings Inc. raised its stake in LENZ Therapeutics by 2,146.2% during the 2nd quarter. Osaic Holdings Inc. now owns 1,168 shares of the company’s stock valued at $34,000 after acquiring an additional 1,116 shares during the last quarter. Institutional investors and hedge funds own 54.32% of the company’s stock.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.